Ultomiris (ravulizumab-cwvz) is a brand-name drug prescribed for certain inflammatory diseases. Ultomiris comes as a solution for intravenous (IV) infusion. It’s given by a healthcare professional, ...
AstraZeneca is making new progress with its Ultomiris expansion plan. On the heels of an FDA approval, the C5 inhibitor has returned with a clinical win in a rare autoimmune disease affecting the ...
Credit: Shutterstock. The approval was based on data from a phase 3 study that included 175 adults with generalized myasthenia gravis who were not previously treated with a complement inhibitor. The ...
When it comes to new drugs, how much are we willing to pay for innovation? That question, touched on by Craig Garthwaite and Benedic Ippolito in their First Opinion on drug prices, deserves a deeper ...
AstraZeneca has been successful at rolling out its long-acting complement C5 inhibitor Ultomiris in the uses approved for its predecessor Soliris – until now, that is. The drugmaker confirmed this ...
Alexion Pharmaceuticals, Inc. ALXN announced that the FDA approved its long-acting C5 complement inhibitor, Ultomiris, for the treatment of children (aged one month and above) as well as adolescents ...
AstraZeneca AZN announced that the FDA has approved its drug Ultomiris for a new rare neurological disease. The approval for long-acting C5 complement inhibitor Ultomiris is for the treatment of adult ...
Replacing a superstar can be difficult, except for the uber talented. Case in point: the Green Bay Packers’ Aaron Rodgers stepping in at quarterback for Brett Favre and not missing a beat. In the ...
Alexion Pharmaceuticals, Inc.ALXN announced that the phase III study of its long-acting C5 complement inhibitor Ultomiris, conducted in complement inhibitor-naive patients with atypical hemolytic ...
(Reuters) - The U.S. Food and Drug Administration on Friday approved Alexion Pharmaceuticals Inc's treatment for a second rare blood disorder, the company said. The treatment, Ultomiris, has already ...
Alexion has the EU approval it needed for Ultomiris, a follow-up to its rare disease therapy Soliris that will lose patent protection in Europe next year. The European Commission has approved ...
According to the analysis conducted by Custom Market Insights (CMI), the Ultomiris drug market is projected to grow at a compound annual growth rate (CAGR) of 31.52% from 2025 to 2034. In 2025, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback